Disease Domain | Count |
---|---|
Neoplasms | 5 |
Endocrinology and Metabolic Disease | 2 |
Nervous System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Diagnostic radiopharmaceuticals | 3 |
Small molecule drug | 1 |
Chemical drugs | 1 |
Antibody drug conjugate (ADC) | 1 |
Target |
Mechanism MAGL modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CDK7 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism MAGL modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date13 Apr 2022 |
Sponsor / Collaborator |
Start Date13 Apr 2022 |
Sponsor / Collaborator |
Start Date16 Nov 2021 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
ICAM1 targeting ADC(TianJin University) ( ICAM-1 ) | Thyroid Cancer More | Preclinical |
11C-PAD ( MAGL ) | Neoplasms More | Preclinical |
11C-MAGL-2-11 ( MAGL ) | Neoplasms More | Preclinical |
B-7-A ( α-synuclein ) | Parkinson Disease More | Preclinical |
18F-MAGL-4-11 ( MAGL ) | Neoplasms More | Preclinical |